Volume | 211,577 |
|
|||||
News | - | ||||||
Day High | 0.710101 | Low High |
|||||
Day Low | 0.6977 |
Share Name | Share Symbol | Market | Stock Type |
---|---|---|---|
Spruce Biosciences Inc | SPRB | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Previous Close |
---|---|---|---|---|
0.71 | 0.6977 | 0.710101 | 0.70 | 0.701 |
Trades | Shares Traded | VWAP | Financial Volume | Average Volume | 52 Week Range |
---|---|---|---|---|---|
1,187 | 211,577 | US$ 0.7043321 | US$ 149,020 | - | 0.6711 - 5.95 |
Last Trade | Type | Quantity | Price | Currency |
---|---|---|---|---|
17:57:29 | formt | 330 | US$ 0.70 | USD |
Spruce Biosciences Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
28.5M | 40.71M | - | 10.09M | -47.92M | -1.18 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Spruce Biosciences News
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical SPRB Price Data
Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 0.70 | 0.7488 | 0.6711 | 0.6996615 | 590,145 | 0.00 | 0.00% |
1 Month | 0.81 | 0.8698 | 0.6711 | 0.7587073 | 706,691 | -0.11 | -13.58% |
3 Months | 3.46 | 5.95 | 0.6711 | 1.55 | 1,418,863 | -2.76 | -79.77% |
6 Months | 1.12 | 5.95 | 0.6711 | 1.65 | 768,484 | -0.42 | -37.50% |
1 Year | 2.09 | 5.95 | 0.6711 | 1.72 | 436,962 | -1.39 | -66.51% |
3 Years | 17.00 | 17.58 | 0.6711 | 3.39 | 645,566 | -16.30 | -95.88% |
5 Years | 17.00 | 35.60 | 0.6711 | 3.75 | 559,653 | -16.30 | -95.88% |
Spruce Biosciences Description
Spruce Biosciences Inc is a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders. The company is developing its wholly-owned product candidate, tildacerfont, as the potential first non-steroidal therapy to offer improved disease control and reduce steroid burden for patients suffering from classic congenital adrenal hyperplasia (CAH). |